Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma

Table 2 Distribution of changes in time-intensity curve parameters in tumors from day 0 to day 7 for 20 hepatocellular carcinoma patients according to modified Response Evaluation Criteria in Solid Tumors response at 2 mo

	Responders (n = 9)		Non-responders (n = 11)
	Day 0	Day 7	Day 0	Day 7
Slope	1.51 [1.31, 1.68]	1.09 [0.84, 1.23]	1.52 [1.22, 1.62]	1.33 [0.86, 1.71]
P value	0.018		0.511
TTP	10.56 [9.33, 12.13]	12.43 [11.94, 13.94]	11.02 [8.53, 12.51]	11.84 [10.15, 13.82]
P value	0.003		0.247
AUC	266.51 [225.38, 296.67]	156.44 [123.05, 178.91]	258.14 [191.61, 299.51]	229.65 [176.10, 269.50]
P value	0.001		0.322

The values represent the median [25^th-75^th percentile]. HCC: Hepatocellular carcinoma; TTP: Time to peak; AUC: Area under the curve.